Biomarin Pharmaceutical (MEX:BMRN) Long-Term Debt : MXN12,412 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Biomarin Pharmaceutical Long-Term Debt?

Biomarin Pharmaceutical's Long-Term Debt for the quarter that ended in Dec. 2024 was MXN12,412 Mil.

Biomarin Pharmaceutical's quarterly Long-Term Debt increased from Jun. 2024 (MXN10,884 Mil) to Sep. 2024 (MXN11,708 Mil) and increased from Sep. 2024 (MXN11,708 Mil) to Dec. 2024 (MXN12,412 Mil).

Biomarin Pharmaceutical's annual Long-Term Debt declined from Dec. 2022 (MXN21,115 Mil) to Dec. 2023 (MXN10,067 Mil) but then increased from Dec. 2023 (MXN10,067 Mil) to Dec. 2024 (MXN12,412 Mil).

Biomarin Pharmaceutical Long-Term Debt Historical Data

The historical data trend for Biomarin Pharmaceutical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Long-Term Debt Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

21,386.78

22,136.19

21,114.54

10,067.34

12,412.02

Biomarin Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															10,067.34	9,851.62	10,884.27	11,708.38	12,412.02

Biomarin Pharmaceutical (MEX:BMRN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Biomarin Pharmaceutical Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MEX:BMRN) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy 0HNC:UK BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.